Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a FOCUS-C9 Clinical Trial of WVE-004 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
July 20, 2021 08:00 ET
|
Wave Life Sciences USA, Inc.
First clinical dosing of a compound using PN backbone chemistry modifications Enrolling participants with C9-ALS, C9-FTD or mixed phenotype FOCUS-C9 is adaptive to enable rapid optimization of...
Wave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency
June 02, 2021 16:52 ET
|
Wave Life Sciences USA, Inc.
First proof-of-concept in vivo data for RNA editing using endogenous ADAR enzymes in alpha-1 antitrypsin deficiency ADAR editing resulted in therapeutically meaningful restoration of circulating...
Wave Life Sciences to Present at Jefferies Virtual Healthcare Conference
May 28, 2021 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update
May 13, 2021 07:30 ET
|
Wave Life Sciences USA, Inc.
Clinical trials underway with next-generation candidates incorporating PN chemistry Clinical data from PN chemistry programs expected in 2022 In vivo ADAR editing data for AATD program on track for...
Wave Life Sciences to Present at RBC Capital Markets Global Healthcare Virtual Conference
May 10, 2021 16:05 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences to Webcast Conference Call of First Quarter 2021 Financial Results on May 13, 2021
May 03, 2021 16:05 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Provides Update on Phase 1b/2a PRECISION-HD Trials
March 29, 2021 16:05 ET
|
Wave Life Sciences USA, Inc.
mHTT results from PRECISION-HD trials do not support further development of WVE-120102 and WVE-120101 No observed change in wtHTT and NfL during trials Advancing Phase 1b/2a trial for WVE-003...
Wave Life Sciences to Present at the Third Annual Stifel CNS Day
March 19, 2021 08:00 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., March 19, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
March 04, 2021 07:00 ET
|
Wave Life Sciences USA, Inc.
Strong execution in 2020 sets stage for advancing five clinical programs and novel ADAR editing modality in 2021 Data from ongoing PRECISION-HD and OLE clinical trials for Huntington’s disease...
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021
February 23, 2021 08:00 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...